[1][2][3] and served on a number of other university boards, including the board of directors of the International House at UC Berkeley, where he was the Treasurer[4], as well as the board of Cal State East Bay University[5]. Prior to founding our company, Dr. Eltoukhy held various positions at Illumina, Inc. from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. case Guardant Health Board Member Related Hubs Education Family SAN FRANCISCO, CA - August 31, 2021 - Ellipsis Health, pioneer of the first voice vital sign to quantify and manage depression and anxiety at scale, today announced that it has raised $26 million in Series A funding to further its measurement-based approach to identifying and quantifying behavioral health conditions.Through voice technology, Ellipsis Health empowers people to take control . The two researchers met as graduate students at Stanford in 2002 and then worked together at. Petition for Dissolution of Marriage/Domestic Partnership. Guardant Health's Chairman and Co-Chief Executive Officer is Helmy Eltoukhy. Helmy Eltoukhy is CEO of leading precision oncology company Guardant Health, which he cofounded with AmirAli Talasaz over 8 years ago. Black U.K. Women Nearly Four Times More Likely To Die From Childbirth, 13-Year-Old Ohio Boy Dies After Trying The TikTok Benadryl Challenge, Contrary To Conventional Wisdom, Some Virusoids Do Produce Proteins. How do you think this will change the world? Two crossed lines that form an 'X'. Under Eltoukhys direction as CEO, Guardant Health raised over one billion dollars in financing, launched three products, established collaborations with oncology researchers, and gained recognition as a healthcare innovator inliquid biopsyapproaches used for cancer diagnosis and research. Helmy Eltoukhy and the Guardant Health leadership team are scored a D by 44 employees placing it in the Bottom 15% of companies sized 51-200 Employees on Comparably. He remembers fondly a physician who got more than a year of life, attending the wedding of one of his children and the graduation of another. Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients. Consequently, in the mid 1990s, he co-founded two registered investment entities in San Francisco: Aurum Capital Management,[27] an investment advisory firm, and Aurum Securities, a broker-dealer. Based on our data team's research, Helmy Eltoukhy is the Guardant Health's CEO. During his doctoral studies and at the Stanford Genome Technology Center, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. AmirAli Talasaz, and Helmy Eltoukhy, for changing Rodney Gibson's life with your liquid biopsy test. 241 Jobs. Guardant Health was founded to pioneer non-invasive liquid biopsy approaches for cancer diagnosis, monitoring, personalized medicine treatment, and research. A simple blood test to detect cancer at all stages of the disease has the power to change the world by increasing testing and screening rates which will help curb cancer mortality rates once and for all. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. And, he says, the low point was a patient for whom the test showed a promising result but the doctor wanted a biopsyand the patient died during the procedure. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. Scaling applies to people, not just companies one has to keep learning new skills, on and off the job, to be able to continue adding value to hyper-scaling companies. Prenatal testing was DNA sequencings first big market. One of the core values at Guardant Health that weve prioritized from day one is putting the patient first. Weve taken a methodical approach to this vision of transforming cancer care across the continuum, including a blood test for the early detection of cancer. ; Additional Info: Comment Final Declaration of Disclosure and Income & Expense Declaration filed. All Rights Reserved. 2023 Fortune Media IP Limited. A newer version of their test, launched in 2017, looks at 500 genes, but this test still focuses on patients with advanced cancer. And the best part of all, documents in their CrowdSourced Library are FREE! Guardant Health's current Chief Executive Officer is Helmy Eltoukhy. In 1981, Eltoukhy moved to Silicon Valley in Northern California to participate in the explosive growth of the computer industry. The blood is full of pieces of DNA shed by cells. Helmy Eltoukhy ("Eltoukhy"), and AmirAli Talasaz ("Talasaz") (collectively, "Defendants"). BREAKING: Tiny biotech successfully treats blindness. Helmy Eltoukhy is an American scientist and entrepreneur, best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. Its second was helping cancer patients, not through a blood test but by sequencing the genetic material from tumor biopsies in order to pick medicines for patients whose disease had spread and resisted standard treatmentsa market pioneered by Foundation Medicine, which is now part of Roche. There are 14 older and 1 younger executives at Guardant Health Inc. We certainly believed that our liquid biopsy could make a difference in patient care, but were surprised to discover all the unexpected ways it could. One success mindset that I think is important is intellectual humility. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. It indicates a way to close an interaction, or dismiss a notification. Guardant Health Co-founder & CEO 2013 Board and Advisor Roles Number of Current Board & Advisor Roles 1 Helmy Eltoukhy is the Board Member at Guardant Health. filed a(n) Coldwell Banker Realtys Joe Piazza was 72 Barrys listing broker. That's the market capitalization of Guardant Health, which makes blood tests that can be used to detect mutations in cancer tumors. That will be a competitive landscape. Our reports have gotten simpler and simpler over the years by narrowing their scope to what truly matters for patient care. 03/21/23; Press Release; Guardant chief executive Helmy Eltoukhy addresses employees at the blood testing startup, with [+] cofounder AmirAli Talasaz in the background. methods for texturing a magnetic disc substrate. In addition, Meghan Joyce, COO, and EVP of Platform at Oscar Health will join the Board as an Independent Director. The method has drawn plenty of interest -- and capital -- despite initial skepticism. Whats happened in the last decade has really been the tipping point. About half of San Mateo Countys 27 submarkets, including Atherton, saw single-family sales volume drop from September to October, according to MLSListings data. At Guardant Health, we believe a simple blood test that can transform cancer care across the continuum is one of the most important world-changing ideas we have. Learn More on Guardant Health's active insiders. The company was acquired by Illumina in 2008 and over the next few years Illumina made great strides in achieving an important milestone of reducing the cost of sequencing a human genome down to $1,000. Unlike innovation in broad technology, in healthcare, you have the added barriers of clinical evidence, regulatory approval, reimbursement, etc. Helmy is an entrepreneur and pioneer in the biotech industry. Your career? During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several NIH National Human Genome Research Institute grants. Named as aWorld Economic ForumTechnology Pioneer and to Fierce Biotech's Fierce 15 list. This page was last edited on 17 July 2020, at 10:42. Each owns shares in Guardant that are worth in excess of $200 million. Eltoukhy has also authored many patents and publications in semiconductor and magnetic thin film technology. Eltoukhy's work has spanned three different careers, in science and academia, where he has been considered one of the pioneers of digital disk storage technology, as an entrepreneur, who co-founded four successful startups in two different industries, and as a money manager and quant trader with a track record of thirty-two profitable years in a row. See the full leadership team at Craft. He received his Ph.D., M.S. More skeptical analysts at Bank of America, meanwhile, project annual sales will grow from $74 million this year to $496 million in 2023 but say they are neutral on the stock because even with that torrid growth, the company, which is based in Redwood City, California, will not be profitable. They realized it was really ovarian cancer! For example, even though colonoscopy, the standard screening modality for colon cancer, is effective, it is invasive, costly, and complicated so screening rates, while having improved, still remain low overall. Likewise, the Eltoukhy Family Foundation funded endowed fellowships for the benefit of Egyptian/Middle Eastern students at the International House at UC Berkeley.[32]. Our companys first blood test, or liquid biopsy, for use with advanced cancer patients, is easier, faster, and less invasive than traditional tissue biopsy, revealing the genomic mutations of a patients cancer to inform precision medicine, an increasingly essential branch of therapy that can be more effective and less toxic than traditional one size fits all chemotherapy or immunotherapy. ; Additional Info: Comment Final Declaration of Disclosure and Income & Expense Declaration filed. As the CEO of Guardant Health, Inc., Dr. Eltoukhy earned a total compensation package of $13,665.00 in 2021. He joined the Stanford Genome Technology Center as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. Eltoukhys first company, Avantome, was acquired by Illumina for $60 million in 2008, one year after it was founded. I cover science and medicine, and believe this is biology's century. Which principles or philosophies have guided your life? Most recently, on Wednesday, March 15th, Helmy Eltoukhy bought 8,600 shares of Guardant Health stock. FinancialFinancial info for ELTOUKHY, HELMY; eFile Online Payment Receipt # 2023-005493-HOJ ELTOUKHY, HELMY $20.00, FinancialFinancial info for ELTOUKHY, HELMY; Transaction Assessment $20.00, DocketStipulation. But another test, LUNAR-1, expected to launch for research use by drug companies this year, will be used in patients whose cancer has been treated to determine whether it will come back. You have the added complexities of proving the clinical utility of your test to improve healthcare outcomes. The co-founder of startups Avantome and Guardant Health, Eltoukhy was named to Time (magazine) 's inaugural 50 Most Influential People in Healthcare (2018) [3] [4] and Fortune's 40 . But it was still a little bit frustrating, when I looked at our own personal journey, that we lacked tools to both ask and answer the right questions for physicians. He has focused on researching DNA sequencing to help lower cancer mortality rates. Its solutions include treatment selection, recurrence detection, and early detection. Helmy Eltoukhy is an American scientist, entrepreneur, and investor best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. Helmy Eltoukhy, Ph.D. is the co-founder and chairman of the board of directors for Guardant Health and has served as the company's Co-Chief Executive Officer since August 2021. Helmy was named to Fortune's 40 under 40 in 2017 and the San Francisco Business Times 40 under 40 in 2019, and was one of Time Magazine's 50 Most . The most recent stock trade was executed by John G. Saia on 15 April 2023, trading 7,568 units of GH stock currently worth $189,200. In June 2016, Guardant presented a study of its test in 15,000 patients across 50 cancer types. Liquid biopsy has been around since the 1950s. For what we do, having respect for the complexity of biology and for learning from others is so important. Service Date: 02/1/2022, Clerk's Notice of Hearing. FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. There are 2 executives at Guardant Health Inc getting paid more, with MichaelWiley having the highest compensation of $2,216,070. The dynamic duo of Helmy and AmirAli believes that the key to conquering cancer is to expand efforts to detect the cancers most likely to be cured through early intervention and access to their molecular information throughout all stages of the disease. It was a great time, obviously, in their history, says Eltoukhy. Eltoukhy says revealing the study was one of his best days at Guardant. Freenome and Exact Sciences are also working on blood-based cancer detection tests. Related Topics: News, Cancer Care, Oncology, Science, Healthcare Comment Show comments (The current version examines 73 genes and has a list price of $7,800.). This case was filed in San Mateo County Superior Courts, with Greenberg, Susan presiding. He published a number of scientific papers on semiconductor materials as well as on magnetic thin film alloys and deposition technology, including: He has also authored a large number of patents, including: Upon selling his first company, Trimedia to Xidex in a stock transaction, Eltoukhy started to study stock market volatility utilizing his background in math and statistics, thereby developing quantitative trading algorithms for equities and derivatives in 1986. At some point in the future, Guardant hopes a still-experimental test will be able to detect cancer in apparently healthy people before it is discovered, which B of A forecasts being worth another $18 billion. [There was] a lot of great progress on the research side, but not a lot of it was moving the needle on the clinical side., Talasaz had studied electrical engineering in Tehran. Before Atef Eltoukhy worked as a scientist at IBM's San Jose research center, before he co-founded a string of tech companies and before he took some of them public, his first Silicon Valley job. Guardant raised $360 million in May, and aims to sequence more than 1 million cancer patients' DNA within five years. Guardant Health is part of the Medical Specialists industry, and located in California, United States. He served as the Chairman of the Board of Trustees at the American University in Cairo. It was this personal healthcare odyssey that led me to realize that physicians desperately need much more informative tools to be able to ask and answer the right questions regarding their patients. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) as a postdoctoral fellow in 2006 to work on low-cost DNA sequencing technologies. The Foundation was established in 2009 by Matthew Logelin, who lost his wife Elizabeth in 2008. . As CEO of the company, he helped raise more than $2.5 billion in funding for the company and took it public in October 2018. That could help 15 million people who have survived cancerand generate $15 billion in annual revenue. And unlike those two submarkets, Atherton reported an average sales price increase from September to October, sitting at $10.6 million at the end of last month, MLSListings data show. Guardant Health Inc executives and other stock owners filed with the SEC include: Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens, Stocks and cryptocurrency portfolio tracker. Over the last 5 years, insiders at Guardant Health Inc have traded over $2,653,397,513 worth of Guardant Health Inc stock and bought 2,433,042 units worth $45,037,095 Divorce,Separation - and B.S. There are barriers to traditional standard-of-care testing and screening modalities that a simple blood test, which is easier, faster, and less invasive, can help overcome. This case was filed in San Mateo County Superior Courts, Southern Branch Hall of Justice and Records located in San Mateo, California. Sell-side analysts at Cowen, Leerink Partners, J.P. Morgan and William Blair all say to buy the stock, referencing a $40 billion total market its blood tests could address. Executive Summary. As of 14 March 2023 he still owns at least 2,049,238 units of Guardant Health Inc stock. Our recent success in bringing to market Guardant360 CDx, the first FDA-approved comprehensive liquid biopsy for all solid cancers, and a test that is covered by many private payers and Medicare for all advanced tumors, has provided us with many important learnings as we continue to look ahead to bringing future products to market for more patients earlier in the cancer care continuum. Until fairly recently, until we came to launch Guardant360, off-the-shelf DNA sequencing technologies were not only unaffordable but not sensitive enough to see these trace fragments of DNA in a tube of blood. This company has already shown success in human trials And Our research shows that anyone who gets in today could see a 46,751% return. Since then, Guardant Healths liquid biopsy tests have been used by over 9,000 oncologists in over 150,000 samples to date. ; Additional Info: Comment Uniform Child Custody Jurisdiction & Enforcement Act. At Illumina, Helmy was Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. Discover the immediate steps you need to take now. and B.S. DocketDeclaration Under UCCJEA. Learning to hire, manage, lead, write, present more effectively are all necessary growth curves that young founders must dedicate time towards. Lets now move to the main focus of our interview. /s/ Michael Wiley, as Attorney-in-Fact for Helmy Eltoukhy: 04/01/2020 ** Signature of Reporting Person: Date: Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Significant News Only. One critical advancement made during COVID was the growing reliance on the life-saving power of Real-World . From left: Beth Seidenberg, Vijay Pande and Annie Lamont. PALO ALTO, Calif., (BUSINESS WIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data. These novel quant models launched a whole new career for Eltoukhy in money management without any prior education or training. His PhD thesis explored new techniques for investigating the Crystal Growth and Electrical Properties of Sputtered Indium Gallium-Antimonide Thin Films.[6]. PURCHASE A LICENSE. Shares have doubled from the $19 price set in the companys October 4 initial public offering, which raised $273 million. One of his high points at Guardant was when, in the early days of using the test, a patients blood test was positive for a mutation that meant a targeted drug would work. In June 2007, he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. Learn More about insider trades at Guardant Health. Eltoukhy's graduate education included a Master of Science degree in Metallurgical Engineering from the Cairo University School of Engineering as well as graduate studies at the American University in Cairo from 1973 to 1975 and a PhD from the University of Illinois, Urbana-Champaign in 1978. Superiorwith Greenberg, Susan presiding. Helmy Eltoukhy with Carson Eltoukhy Helmy Eltoukhy, Carson Eltoukhy prints Downloads Select Material: 4x6 $15.00 5x7 $20.00 8x10 $30.00 8x12 $30.00 8xWallet $17.95 Add to cart SHARE Choose if you want to purchase a print or a digital download of this photo Choose what type of print material you would like Superior Courts You really need to get the necessary clinical evidence to prove to oncologists that this improves upon the current standard of care or serves an unmet medical need. so these systems make it harder to have Black Mirror scenarios, though dont get me wrong they can happen in healthcare too. Learn More on Helmy Eltoukhy's salary. The family sponsored the Eltoukhy Family Fellowship at Stanford University,[30][31] in order to provide Egyptian and Middle Eastern students with opportunities for higher education in Silicon Valley. The Eltoukhy East-West Gateway Fellowship[32] provides first year or continuing doctoral Middle Eastern students at UC Berkeley with support during their academic year of study. in the jurisdiction of San Mateo County. Before we dig in, our readers would like to get to know you a bit. If you do not agree with these terms, then do not use our website and/or services. Eltoukhy didnt respond to requests for comment. [28], The Eltoukhy family's philanthropic initiatives are focused on education in the U.S. and Egypt and are funded and managed by the Eltoukhy Family Foundation[29]. Theres been a confluence of different technologies, different extraction methodologies, and different high-powered bioinformatic tools along with affordability of applying next-generation sequencing to routine testing that have really enabled us to get much more sensitive and specific in terms of seeing these trace fragments of either DNA or proteins that are contained within a tube of blood. This landmark study is one of the largest of its kind, enrolling 10,000 American men and women aged 4584 for early colorectal cancer detection, and will be an important milestone in bringing to market a blood test that can detect early signs of cancer in asymptomatic people. The estimated net worth of Helmy Eltoukhy is at least $51.23 million as of March 15th, 2023. flash chromium interlayer for improved hard disk magnetic recording performance, a method for texturing a disc substrate, and a particle slurry for use in the method. ; Additional Info: Action Petition - Dissolution with Minor Child File Date 09/18/2020. 58% of the management team is White. To be honest, there arent many significant drawbacks to liquid biopsy. Atef Eltoukhy was born in Sharkia, Egypt on February 3, 1951. Helmy Eltoukhy is an American scientist and entrepreneur, best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. We have known this from the start and weve approached all of our products systematically with these barriers in mind. Getting these 80% of patients tested would result in significant savings to the healthcare system and much better overall survival for cancer patients. San Mateo County To address these needs and in collaboration with the Stanford Genome Technology Center and the Stanford Nanofabrication Group, we are designing and building a portable, CMOS-based lab-on-chip that is suitable for a variety of applications, such as for, DNA sequencing, gene expression analysis and pathogen detection. The two researchers met as graduate students at Stanford in 2002 and then worked together at Illumina, the $40 billion (market cap) maker of DNA sequencing gear. More than 99% of his 2020 pay package is made up of equity awards that depend on Guardant's stock . In 2007, he co-founded Avantome to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing until its acquisition by Illumina in August 2008. Why is this public record being published online? Cases involving marriage dissolutions or divorces, Court Trial - Short Cause. The test came back with genomic mutations that were not consistent with pancreatic cancer, so her physician ran a few more tests. Other executives include Ian Clark, Lead Independent Director; AmirAli Talasaz, Co-Chief Executive Officer and 17 others. Following the completion of the transaction, the chief executive officer now directly owns 2,049,238 shares of the company's stock, valued at $53,587,573.70. Our LUNAR-2 program is developing a multi-cancer blood test that will first focus on CRC, with our ECLIPSE trial planned to finish enrollment in 2021. If you build it, will they come? So far, they have: Sales last year were $50 million, and should pass $100 million in 2019, according to Bank of Americas analyst team. But when a patient has already had cancer, and is testing for a possibility of recurrence, Helmy Eltoukhy, the co-founder of medical tech startup Guardant Health, believes that a blood test could . Everything else will follow." The corporate mailing address for Dr. Eltoukhy and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Get notified the next time Helmy Eltoukhy buys or sells Guardant Health stock. The co-founder of startups Avantome and Guardant Health, Eltoukhy was named to Time Magazines inaugural 50 Most Influential People in Healthcare (2018) and Fortunes 40 under 40 (2017). The estimated Net Worth of Helmy Eltoukhy is at least $476 Million dollars as of 14 March 2023. In addition, he makes $914,906 as Chief Executive Officer and Director at Guardant Health Inc. Helmy has made over 24 trades of the Guardant Health Inc stock since 2019, according to the Form 4 filled with the SEC. Technology is Exponential, Humans are not. In-depth Interviews with Authorities in Business, Pop Culture, Wellness, Social Impact, and Tech. This doesnt need breakthrough innovation, but can happen through just more testing. The largest trade he's ever made was exercising 565,192 units of Guardant Health Inc stock on 1 January 2021 worth over $13,847,204. Nathaniel Gage, pioneer in the scientific understanding of teaching. The co-founder of startups Avantome and Guardant Health, Eltoukhy was named to Time Magazine's inaugural 50 Most Influential People in Healthcare (2018) and Fortune's 40 under 40 (2017). Courtesy of Seidenberg . The stock was acquired at an average cost of $26.15 per share, with a total value of $224,890.00. Dr. Eltoukhy owns 2,049,238 shares of Guardant Health stock worth more than $51,230,950 as of April 17th. What Is Gain Of Function Research, And Why Should It Be Banned? Helmy Eltoukhy is CEO of leading precision oncology company Guardant Health, which he cofounded with AmirAli Talasaz over 8 years ago. Yet the 10 percent decline in Atherton wasnt as severe as in Woodside and Hillsborough, two other affluent enclaves in the county where sales volume plummeted by more than half during that time, the data show. There are 700,000 in the U.S. Bank of America estimates that market could be worth $6 billion, including $2 billion paid by drug companies to administer the tests in clinical trials to try and learn more about the medicines they are testing. We will email you when the process is complete. Terms & Conditions. Enter your email address below to get our daily insider buying and selling report. Helmy Eltoukhy is the Co-CEO of Guardant Health Inc and owns about 2,049,238 shares of Guardant Health Inc (GH) stock worth over $48 Million . Fred Swaniker, co-founder of African Leadership Academy, CEO and co-founder of African Leadership University. The corporate mailing address for Dr. Eltoukhy and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. This Malibu trailer park is coveted by the rich, the famous and the surfers, Fannie Mae keeps secret blacklist of properties, Watch: Developer Patrick Carroll "spits" on restaurant manager, Pair of Atherton estates sell for combined $51M, Atherton retains top spot for regions wealthiest zip code, Redeveloped Atherton estate sells for $22.5M. Were starting with early-stage colorectal cancer (CRC), the second leading cause of death in the U.S. and a disease where an estimated 1030% of early-stage patients recur within five years. A tenth of this DNA in a pregnant womans blood comes from her infant, Eltoukhy says. 2020-02-26. The Inception Overview. ; Additional Info: Judicial Officer Cho Sharon K. Hearing Time 9:00 AM Cancel Reason Vacated Comment 2/27/23-3/10/23 5 DAY ESTIMATE, Financial info for ELTOUKHY, HELMY; eFile Online Payment Receipt # 2023-005493-HOJ ELTOUKHY, HELMY $20.00, Financial info for ELTOUKHY, HELMY; Transaction Assessment $20.00, Stipulation. MOUNTAIN VIEW, CALIFORNIA - NOVEMBER 03: Helmy Eltoukhy and Carson Eltoukhy attend the 2020 Breakthrough Prize Ceremony at NASA Ames Research Center on November 03, 2019 in Mountain View, California. Growth and Electrical Properties of SputterDeposited SingleCrystal GaSb Films on GaAs Substrates. We first launched our liquid biopsy back in 2014. Guardant Health Location 3100 Hanover St, Palo Alto, California, 94304, United States Description Read More Industry grace protestant reformed church, confucianism vs buddhism similarities, texas powerball numbers,
O Magnum Mysterium Analysis,
Why Is My Ferret Sneezing,
Remove Viper Alarm,
Nurs 4685 Capstone Module 1,
Articles H
